PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

• Status: Completed
• Trial end date: 2016-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective-retrospective study to determine if the expression of the miRNA's miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer. The present study will utilize FFPE tumor samples collected from patients enrolled in the PETACC-8 study conducted by the Fédération Francophone de Cancérologie Digestive (FFCD). This phase 3 clinical trial prospectively randomized fully resected stage III colon cancer patients to receive adjuvant treatment with either FOLFOX-4 plus cetuximab or FLOFOX-4 alone.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IntegraGen SA
• Collaborators: Exystat; Federation Francophone de Cancerologie Digestive
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

• Patient included in PETACC08 study

• Signed informed consent for translational study

• FFPE tumor sample available for miR-31-3p and miR-31-5p expression testing

Exclusion Criteria:

• Patient who have withdrawn their consent for PETACC08 and/or for PETACC08 translational study